Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review

Frontiers in Immunology

Gurupreet S. Sethi¹  Vivek Dharwal¹  Amarjit S. Naura¹ 

[1] Department of Biochemistry, Panjab University, Chandigarh, India;

关键词: asthma;    acute lung injury;    chronic obstructive pulmonary disease;    lung inflammation;    poly(ADP-ribose)polymerase;    NF-κB;   

DOI  :  10.3389/fimmu.2017.01172

来源: DOAJ

【 摘 要 】

Asthma, acute lung injury (ALI), and chronic obstructive pulmonary disease (COPD) are lung inflammatory disorders with a common outcome, that is, difficulty in breathing. Corticosteroids, a class of potent anti-inflammatory drugs, have shown less success in the treatment/management of these disorders, particularly ALI and COPD; thus, alternative therapies are needed. Poly(ADP-ribose)polymerases (PARPs) are the post-translational modifying enzymes with a primary role in DNA repair. During the last two decades, several studies have reported the critical role played by PARPs in a good of inflammatory disorders. In the current review, the studies that address the role of PARPs in asthma, ALI, and COPD have been discussed. Among the different members of the family, PARP-1 emerges as a key player in the orchestration of lung inflammation in asthma and ALI. In addition, PARP activation seems to be associated with the progression of COPD. Furthermore, PARP-14 seems to play a crucial role in asthma. STAT-6 and GATA-3 are reported to be central players in PARP-1-mediated eosinophilic inflammation in asthma. Interestingly, oxidative stress–PARP-1–NF-κB axis appears to be tightly linked with inflammatory response in all three-lung diseases despite their distinct pathophysiologies. The present review sheds light on PARP-1-regulated factors, which may be common or differential players in asthma/ALI/COPD and put forward our prospective for future studies.

【 授权许可】

Unknown